Consano Bio Unveils C-1101: A Novel Therapy for Chronic Sciatica Management

Consano Bio Advances Novel Therapy for Chronic Sciatica

In a significant development for the field of pain management, Consano Bio, a clinical-stage biotechnology company founded in 2023, prepares to showcase its innovative therapeutic candidate, C-1101, at the BIO Investment & Growth Summit in Miami. Scheduled for March 2, 2026, CEO Andrew Hall aims to provide insights into the company’s strategic roadmap and clinical advancements concerning this first-in-class, platelet-derived multi-protein biologic therapeutic. The focus on C-1101 aligns with Consano Bio’s mission to address chronic lumbosacral radiculopathy (LSR), commonly known as chronic sciatica, which currently lacks FDA-approved pharmaceutical treatments despite its prevalence and the significant burden it places on individuals and healthcare systems.

C-1101 represents a novel approach to treating chronic sciatica, a condition where spinal nerve roots become compressed or damaged, leading to debilitating pain, numbness, and weakness in the legs. The innovative therapy, extracted from human platelets sourced from healthy donors, offers a controlled formulation of cytokines, growth factors, and matrix proteins—vital components that may activate the body’s natural healing processes. By delivering this multi-protein solution via epidural injection, C-1101 is designed to effectively modulate inflammation and promote cellular repair directly at the site of nerve injury. This targeted therapeutic modality marks a significant progression in orthopedic treatment options, particularly in conditions characterized by substantial pain and limited relief.

Consano Bio's strategic approach emphasizes ensuring consistency in the protein concentrations delivered by C-1101, addressing a common challenge faced by many biologic therapies which often exhibit variability in their components. As the company conducts ongoing clinical studies to assess the safety, efficacy, and regulatory pathways for C-1101, it actively seeks partnerships and investment opportunities to support the advancement of late-stage trials and eventual commercialization. With an array of clinical updates anticipated in the near future, Consano Bio is poised to make impactful contributions to pain management strategies in orthopedic medicine.

In addition to the presentation at the summit, Consano Bio’s management team plans to engage in one-on-one discussions with investors and potential partners. These meetings are designed to explore collaboration opportunities that could facilitate financing and advance clinical strategies for C-1101. By focusing on producing a reliable and effective treatment for chronic sciatica, Consano Bio underscores its commitment to revolutionizing healthcare outcomes for individuals suffering from debilitating orthopedic conditions.